Oscar Health, Inc. (NYSE:OSCR) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Oscar Health, Inc. (NYSE:OSCR) have been given a consensus recommendation of “Moderate Buy” by the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $19.75.

A number of brokerages recently weighed in on OSCR. Wells Fargo & Company raised their price target on shares of Oscar Health from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Wednesday, June 12th. The Goldman Sachs Group upped their price target on Oscar Health from $16.00 to $21.00 and gave the company a “neutral” rating in a research note on Thursday, May 9th. Raymond James began coverage on Oscar Health in a report on Friday, March 22nd. They set an “outperform” rating and a $20.00 price objective for the company. Bank of America reaffirmed a “neutral” rating and issued a $21.00 target price (down previously from $25.00) on shares of Oscar Health in a research note on Thursday, May 30th. Finally, Robert W. Baird initiated coverage on shares of Oscar Health in a research note on Thursday, May 30th. They set an “outperform” rating and a $28.00 price target for the company.

Oscar Health Stock Down 10.4 %

Shares of NYSE:OSCR opened at $15.82 on Wednesday. The company has a market capitalization of $3.75 billion, a PE ratio of -39.55 and a beta of 1.68. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.10 and a current ratio of 1.10. Oscar Health has a 52 week low of $4.72 and a 52 week high of $23.44. The company’s fifty day moving average is $19.49 and its 200-day moving average is $15.42.

Oscar Health (NYSE:OSCR) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.34. Oscar Health had a negative return on equity of 5.77% and a negative net margin of 0.82%. The company had revenue of $2.14 billion for the quarter, compared to analyst estimates of $1.99 billion. During the same quarter in the previous year, the firm earned ($0.18) earnings per share. The business’s revenue was up 45.8% on a year-over-year basis. Equities research analysts predict that Oscar Health will post -0.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Steven Wolin sold 18,607 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $19.46, for a total value of $362,092.22. Following the completion of the transaction, the chief operating officer now directly owns 65,316 shares in the company, valued at approximately $1,271,049.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Victoria Baltrus sold 7,674 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $19.46, for a total value of $149,336.04. Following the sale, the chief accounting officer now directly owns 127,754 shares in the company, valued at $2,486,092.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Steven Wolin sold 18,607 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $19.46, for a total value of $362,092.22. Following the transaction, the chief operating officer now owns 65,316 shares of the company’s stock, valued at $1,271,049.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 81,655 shares of company stock worth $1,589,006. Corporate insiders own 25.11% of the company’s stock.

Hedge Funds Weigh In On Oscar Health

Several hedge funds have recently made changes to their positions in the business. Formation8 GP LLC bought a new stake in Oscar Health during the 4th quarter worth about $47,480,000. Price T Rowe Associates Inc. MD boosted its position in Oscar Health by 153.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,978,152 shares of the company’s stock valued at $59,156,000 after purchasing an additional 2,409,160 shares during the last quarter. Vanguard Group Inc. grew its stake in Oscar Health by 18.6% in the third quarter. Vanguard Group Inc. now owns 14,127,934 shares of the company’s stock valued at $78,693,000 after purchasing an additional 2,211,743 shares in the last quarter. Iron Triangle Partners LP acquired a new position in shares of Oscar Health during the 4th quarter worth approximately $18,781,000. Finally, Ancient Art L.P. raised its stake in shares of Oscar Health by 91.9% during the 3rd quarter. Ancient Art L.P. now owns 2,793,141 shares of the company’s stock worth $15,558,000 after purchasing an additional 1,337,987 shares in the last quarter. 75.70% of the stock is owned by institutional investors.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.